There is a P3 underway (registrational?) of IPI-145 v. Ofatumumab in R/R CLL. Will this even be relevant by the time the study is completed with Ibrutinib on the market? Also, you make a good point that there are a number of PI3Ki in development.
INFI data may speak for themselves but will anyone care?
Just digging into INFI and am concerned about how IPI-145 could compete eventually with Ibrutinib in R/R CLL. Will there need to be a Ibrutinib v IPI-145 eventually? From what I have been able to find, I am not sure that is even a contest in CLL. What are your thoughts?